4. Most common treatment-related adverse events*.
| Adverse events | Lapatinib group (N=88) | Trastuzumab group (N=118) | |||
| Events of any grade | Events of grade 3−4 | Events of any grade | Events of grade 3−4 | ||
| *, Safety analysis was conducted on 88 patients in the lapatinib group and 118 patients in the trastuzumab group. | |||||
| Diarrhea | 63 (71.6) | 14 (15.9) | 42 (35.6) | 2 (1.7) | |
| Hand-foot syndrome | 42 (47.7) | 15 (17.0) | 8 (6.8) | 1 (0.8) | |
| Vomiting | 22 (25.0) | 4 (4.5) | 19 (16.1) | 2 (1.7) | |
| Neutropenia | 15 (17.0) | 5 (5.7) | 31 (26.3) | 9 (7.6) | |
| Anemia | 9 (10.2) | 1 (1.1) | 27 (22.9) | 2 (1.7) | |
| Thrombocytopenia | 7 (8.0) | 1 (1.1) | 18 (15.3) | 3 (2.5) | |